The United States Patent and Trademark Office (USPTO) has issued Axcentua Pharmaceuticals the USPTO patent no 7,863,325 B2 entitled “Crystalline Genistein Sodium Salt Dihydrate”. The patent covers Axcentua’s novel crystalline composition of genistein, AXP107-11 or genistein-SSDH and its medical uses. AXP107-11 is currently in phase Ib/IIa clinical trials for pancreatic cancer. Axcentua received the patent granted after an examination period of only 13 months. In addition, Axcentua has several PCT applications in key markets on approximately ten additional crystalline forms of genistein.